Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec Adds Sales Reps For Launch Of HeartMate II As Destination Therapy

This article was originally published in The Gray Sheet

Executive Summary

Thoratec is beefing up its sales force to emphasize physician referrals now that FDA has approved its HeartMate II ventricular assist device as a "destination" therapy for patients who are not candidates for a heart transplant
Advertisement

Related Content

Dick Cheney Discusses Experience With HeartMate II Device
Dick Cheney Discusses Experience With HeartMate II Device
Thoretec Pipeline: HeartMate III Fully Magnetic LVAD Trial Set For 2012
Thoratec Q2 Sales Up 37%; Plans To Divest ITC To Danaher Fall Through
Thoratec Unloads Dx Equipment Unit To Danaher To Help Fund VAD Efforts
Medicare In Brief
Piper Jaffray Healthcare Conference In Brief
Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study
Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study
With Approval Of HeartMate II, Thoratec Aims To Double U.S. Implant Centers

Topics

Advertisement
UsernamePublicRestriction

Register

MT028421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel